1
|
Cailliau A, Nguyen C, Brochet E, Ducrocq G, Iung B, Urena M. Impact of right ventricular function on the outcomes of transcatheter mitral valve replacement implantation. Archives of Cardiovascular Diseases Supplements 2023. [DOI: 10.1016/j.acvdsp.2022.10.153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
2
|
Kikoine J, Urena M, Chong-Nguyen C, Brochet E, Suc G, Ducrocq G, Iung B, Himbert D. Incidence and prognostic impact of early major bleeding after transcatheter mitral valve implantation. Archives of Cardiovascular Diseases Supplements 2023. [DOI: 10.1016/j.acvdsp.2022.10.146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
3
|
Gautier A, Picard F, Ducrocq G, Yedid E, Fox K, Ferrari R, Ford I, Tardif J, Tendera M, Steg G. New-onset atrial fibrillation in chronic coronary syndrome outpatients: Insights from the international CLARIFY registry. Archives of Cardiovascular Diseases Supplements 2022. [DOI: 10.1016/j.acvdsp.2021.09.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
4
|
Chaligné C, Mageau A, Ducrocq G, Ou P, Rouzaud D, Alexandra J, Mutuon P, Papo T, Sacré K. Myocardite aiguë révélant une maladies auto-immune ou inflammatoire: caractéristiques cliniques et suivi. Rev Med Interne 2021. [DOI: 10.1016/j.revmed.2021.10.312] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
5
|
Gautier A, Ducrocq G, Elbez Y, Fox K, Ferrari R, Ford I, Tardif J, Tendera M, Steg G. Chronic coronary syndrome patients with polyarterial disease are a high risk but heterogenous subset of patients. Insights from the CLARIFY registry. Archives of Cardiovascular Diseases Supplements 2021. [DOI: 10.1016/j.acvdsp.2020.10.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
6
|
Kikoine J, Urena M, Brochet E, Nguyen C, Carrasco J, Ducrocq G, Fuchs A, Vahanian A, Iung B, Himbert D. Incidence, clinical impact and treatment outcomes of valve thrombosis after transcatheter mitral valve implantation. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Transcatheter mitral valve implantation (TMVI) is a new treatment option for high-risk surgical patients with degenerated bioprosthesis (ViV), failed annuloplasty rings (ViR) and severe mitral annular calcification (ViMAC). However, limited data exist on transcatheter heart valve thrombosis.
Purpose
The aim of this study was to report the incidence, clinical impact and treatment outcomes of transcatheter heart valve (THV) thrombosis in patients undergoing TMVI.
Methods
All consecutive patients undergoing TMVI in our center between July 2010 and September 2019 were included. A transoesophageal echocardiography and a computed tomography (CT) were performed before hospital discharge and at each clinical visit, at 3 months, at 1 year and yearly after. THV thrombosis was defined as the presence of at least one thickened leaflet with restricted motion suggestive of thrombus confirmed by TOE and/or contrast CT. All patients received anticoagulation therapy with vitamin K antagonists (VKA) and a low dose of aspirin for the first 3 months.
Results
A total of 132 patients underwent TMVI (62 ViV, 36 ViR and 34 ViMAC). Among them, 16 (12.1%) patients had a THV thrombosis. Median age was 67 years old and 56.2% of patients were women. Median time to diagnosis of THV thrombosis was 78 days. Early THV thrombosis was observed in 7 (43.7%) and in 13 (81.2%) patients THV thrombosis occurred within the first 6 months after the procedure. 8 out 9 patients with subacute or late THV thrombosis were not anticoagulated or with subtherapeutic anticoagulation. No stroke or thromboembolic events occurred in these patients. No change in mitral gradient was observed in 14 out 16 patients. VKA were indicated in all patients. THV thrombosis resolved in all but one patient.
Conclusion
THV thrombosis is frequent after TMVI, occurs mainly within the first 6-months after the procedure, are mostly subclinical and resolves after optimization of anticoagulation treatment. An anticoagulation therapy for at least 6 months may be necessary.
Timing of THV thrombosis
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- J Kikoine
- Hospital Bichat-Claude Bernard, Paris, France
| | - M Urena
- Hospital Bichat-Claude Bernard, Paris, France
| | - E Brochet
- Hospital Bichat-Claude Bernard, Paris, France
| | - C Nguyen
- Hospital Bichat-Claude Bernard, Paris, France
| | | | - G Ducrocq
- Hospital Bichat-Claude Bernard, Paris, France
| | - A Fuchs
- Hospital Bichat-Claude Bernard, Paris, France
| | - A Vahanian
- Hospital Bichat-Claude Bernard, Paris, France
| | - B Iung
- Hospital Bichat-Claude Bernard, Paris, France
| | - D Himbert
- Hospital Bichat-Claude Bernard, Paris, France
| |
Collapse
|
7
|
Gautier A, Ducrocq G, Elbez Y, Ferrari R, Ford I, Fox K, Tardif J, Tendera M, Steg P. CCS patients with polyvascular disease are a high risk but heterogenous subset of patients: insights from the CLARIFY registry. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1365] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Introduction
Polyvascular disease constitutes a powerful predictor of cardiovascular events, is found in 10 to 15% of chronic coronary syndromes (CCS) patient. Smoking and diabetes mellitus are strongly associated with polyvascular disease. Risk stratification is key to select the most appropriate therapeutic strategy for a given patient.
Purpose
We aimed to describe 5-year ischaemic risk of CCS patients according to vascular disease phenotype and diabetic or smoking status.
Method
We analyzed data from 32 703 consecutive CCS outpatients (45 countries) enrolled between November 2009 to June 2010 in the prospective observational CLARIFY registry. Three mutually exclusive groups were compared: Coronary artery disease (CAD) alone, CAD with peripheral artery disease (PAD) or cerebrovascular disease (CVD) (CAD+1), CAD with CVD and PAD (CAD+2). Primary outcome was a composite of cardiovascular death, myocardial infarction or stroke, adjusted on age, sex and geographic origin at 5 years.
Results
At baseline, 26440 (80.8%) patients were diagnosed with CAD alone, 4967 (15.2%) had CAD+1, 1296 (4%) had CAD+2. Overall, 9501 (29%) patients were diabetics, 19184 (58.7%) were smokers or ex-smokers and only 9220 (28.2%) were free of these two major cardiovascular risk factors. Primary outcome increasing gradually according to the number of arterial diseases locations from 8.4% (95% CI 8.09–8.73) in patients with CAD alone to 17.4% (95% CI 16.95–17.83) of CAD+2 patients (p<0.001). Subgroup analysis according to diabetes or smoking status further enriched risk stratification from 7% (95% CI 6.48–7.59) in non-diabetic, non-smoking CAD alone patients to 20.3% (95% CI 19.08–21.44) in diabetics and smokers CAD+ 2 patients (Figure 1). Diabetic CAD alone patients had a comparable risk to that of non-diabetic and non-smoking polyvascular patients, 9.8% (95% CI 8.82–10.68) vs 10.3% (95% CI 9.61–10.96), p=0.38. Outcome was similar between polyvascular diabetic patients, regardless of the number of arterial diseases, 15.5% (95% CI 14.31–16.60) for CAD+1 and 15.0 (95% CI 13.88–16.13) for CAD+2, p=0.83. Smoking increased 5-year risk proportionally to the number of symptomatic arterial bed, 8.2% (95% CI 7.72–8.68) vs 11.8% (95% CI 11.18–12.31) vs 17.9% (95% CI 17.18–18.54), respectively for CAD alone, CAD+1 and CAD+2.
Conclusion
CCS patients with polyvascular disease remain at high risk of ischaemic events in the contemporary practice with widespread secondary prevention therapies. Polyvascular is a very heterogenous subset of patients with ischaemic risk varying not only according to the number of vascular bed diseased but also according to smoking and diabetes status, two conditions present in the vast majority of CCS patients. Diabetes confers upfront a maximal increased risk. Identification of higher risk subsets in polyvascular patients can potentially identify those that could derived the greatest benefit from new secondary prevention strategies.
Figure 1
Funding Acknowledgement
Type of funding source: Public hospital(s). Main funding source(s): Assistance Publique-Hôpitaux de Paris
Collapse
Affiliation(s)
- A Gautier
- Bichat Hospital, University Paris-Diderot, INSERM-UMR1148, FACT French Alliance for Cardiovascular T, Paris, France
| | - G Ducrocq
- Bichat Hospital, University Paris-Diderot, INSERM-UMR1148, FACT French Alliance for Cardiovascular T, Paris, France
| | - Y Elbez
- Bichat Hospital, University Paris-Diderot, INSERM-UMR1148, FACT French Alliance for Cardiovascular T, Paris, France
| | - R Ferrari
- Maria Cecilia Hospital, Cotignola, Italy
| | - I Ford
- University of Glasgow, Glasgow, United Kingdom
| | - K.M Fox
- Royal Brompton Hospital Imperial College London, London, United Kingdom
| | - J.C Tardif
- Montreal Heart Institute, Montreal, Canada
| | - M Tendera
- School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland
| | - P.G Steg
- Bichat Hospital, University Paris-Diderot, INSERM-UMR1148, FACT French Alliance for Cardiovascular T, Paris, France
| |
Collapse
|
8
|
Fuchs A, Iung B, Nguyen C, Carrasco J, Cimadevilla C, Kerneis C, Eugene M, Ghodhbane W, Ducrocq G, Brochet E, Provenchere S, Vahanian A, Himbert D, Urena-Alcazar M. Transseptal transcatheter mitral valve implantation versus redo surgical mitral valve replacement for degenerated mitral bioprostheses. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.2633] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
The growing use of surgical bioprostheses raises concerns about a future reoperation for bioprosthesis degeneration. There are few data on outcome after transcatheter mitral valve-in-valve implantation (TMVI) compared with redo surgical mitral valve replacement (SMVR).
Purpose
To compare the feasibility, safety and outcomes of TMVI versus SMVR for degenerated mitral bioprosthesis in high-risk patients.
Methods
In our institution, 52 patients underwent TMVI by transseptal approach and 33 SMVR for degenerated mitral bioprosthesis. The composite endpoint of event-free survival included cardiovascular mortality, stroke, major bleeding, hospitalization for heart failure or mitral valve reintervention.
Results
Mean age and EuroSCORE II were higher in TMVI group vs. SMVR group (age 63±21 years vs. 51±15 years, p=0.002; EuroSCORE II 12.5±12.2% vs. 6.2±3.3%, p=0.001) (Table). In-hospital mortality was 3.8% after TMVI vs. 3.0% after SMVR (p=1.0).
Median follow-up was 2.2 years. At 5 years, survival was 69.7±9.4% after TMVI vs. 86.6±7.6% after SMVR (p=0.10) and event-free survival was lower after TMVI (40.1±9.9% vs 78.7±8.8% respectively, p=0.003) (Figure). In multivariate analysis, older age (p=0.02), neurologic history (p=0.05) and non-elective procedure (p<0.0001) were associated with lower event-free survival, while TMVI vs. SMVR was no longer significant (p=0.17). At last follow-up, 84% patients from TMVI group and 78% from SMVR group were NYHA I-II class. Mean mitral valve gradient and pulmonary artery systolic pressure were respectively 6.8±2.5 mmHg and 45±14 mmHg in TMVI group, and 4.8±2.0 mmHg and 37±11 mmHg in SMVR group.
Conclusion
TMVI is an alternative to SMVR in high-risk patients with degenerated mitral bioprosthesis. Comparison of mid-term results of the two techniques must take into account the differences in patient characteristics.
Event-free survival
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- A Fuchs
- Hospital Bichat-Claude Bernard, Paris, France
| | - B Iung
- Hospital Bichat-Claude Bernard, Paris, France
| | - C Nguyen
- Hospital Bichat-Claude Bernard, Paris, France
| | | | | | - C Kerneis
- Hospital Bichat-Claude Bernard, Paris, France
| | - M Eugene
- Hospital Bichat-Claude Bernard, Paris, France
| | - W Ghodhbane
- Hospital Bichat-Claude Bernard, Paris, France
| | - G Ducrocq
- Hospital Bichat-Claude Bernard, Paris, France
| | - E Brochet
- Hospital Bichat-Claude Bernard, Paris, France
| | | | | | - D Himbert
- Hospital Bichat-Claude Bernard, Paris, France
| | | |
Collapse
|
9
|
Darmon A, Elbez Y, Bhatt DL, Abtan J, Mas JL, Cacoub P, Montalescot G, Billaut-Laden I, Ducrocq G, Steg PG. Clinical characteristics and outcomes of COMPASS eligible patients in France. An analysis from the REACH Registry. Ann Cardiol Angeiol (Paris) 2020; 69:158-166. [PMID: 32778388 DOI: 10.1016/j.ancard.2020.07.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2020] [Accepted: 07/21/2020] [Indexed: 11/28/2022]
Abstract
BACKGROUND Following the publication of the COMPASS trial, the European Medicines Agency has approved a regimen of combination of rivaroxaban 2.5mg twice daily and a daily dose of 75-100mg acetylsalicylic acid (ASA) for patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischemic events. However, the applicability of such a therapeutic strategy in France is currently unknown. AIMS To describe the proportion of patients eligible to COMPASS in France, their baseline clinical characteristics and the rate of major adverse cardiovascular events, using the REACH registry. METHODS From the the REduction of Atherothrombosis for Continued Health (REACH) registry database, a large international registry of patients with, or at risk, of atherothrombosis, we analyzed patients included in France with either established CAD and/or PAD and fulfilling the inclusion and exclusion criteria of the COMPASS trial. The ischemic outcome was a composite of cardiovascular (CV) death, myocardial infarction (MI), or stroke, and serious bleeding were defined as haemorrhagic stroke or bleeding leading to hospitalization or transfusion. RESULTS Among more than 65000 patients enrolled in REACH, 2.012 patients were evaluable and enrolled in France. Among them, 1194 patients (59.3%) were eligible to COMPASS. The main reasons for exclusion of the COMPASS trial, were high bleeding risk (59.1%), anticoagulant use (43.4%), requirement for dual antiplatelet therapy within 1 year of an ACS or PCI (24.7%). In the "COMPASS eligible population", the rate of MACE (CV, MI and stroke) at 4 years follow-up was 13.4% [11.3-15.8], and serious bleeding was 2.5% at 4 years [1.6-3.4]. Patients with polyvascular disease (n=219) had the highest rate of MACE, compared with patients with CAD only and PAD only (19.1% [13.9-26.1] vs. 11.6% [9.1-14.8] vs 13.2% [9.2-18.8], P<0.0001, respectively). CONCLUSION The COMPASS therapeutic strategy in France appears to be applicable to more than half of CAD or PAD patients. This population appears at high residual risk of atherothrombotic events, and patients with polyvascular disease experienced the highest rate of events.
Collapse
Affiliation(s)
- A Darmon
- FACT, French Alliance for Cardiovascular Trials, Département Hospitalo-Universitaire FIRE, Hôpital Bichat, Paris, France; Université de Paris, assistance publique-Hopitaux de Paris, Paris, France
| | - Y Elbez
- FACT, French Alliance for Cardiovascular Trials, Département Hospitalo-Universitaire FIRE, Hôpital Bichat, Paris, France
| | - D L Bhatt
- Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, USA
| | - J Abtan
- FACT, French Alliance for Cardiovascular Trials, Département Hospitalo-Universitaire FIRE, Hôpital Bichat, Paris, France; Université de Paris, assistance publique-Hopitaux de Paris, Paris, France
| | - J L Mas
- Department of Neurology, Sainte-Anne Hospital, Paris Descartes University, Inserm U1266, Paris, France
| | - P Cacoub
- Sorbonne Universités, UPMC Université Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), 75005 Paris, France; INSERM, UMR_S 959, 75013 Paris, France; CNRS, FRE3632, 75005 Paris, France; Department of Internal Medicine and Clinical Immunology, Groupe Hospitalier Pitié-Salpêtrière, AP-HP, 75013 Paris, France
| | - G Montalescot
- ACTION Study Group, INSERM UMRS 1166, Institut de Cardiologie, Hôpital Pitié-Salpêtrière (AP-HP), Sorbonne Université, Paris, France
| | | | - G Ducrocq
- FACT, French Alliance for Cardiovascular Trials, Département Hospitalo-Universitaire FIRE, Hôpital Bichat, Paris, France; INSERM U1148, LVTS, Paris, France; Université de Paris, assistance publique-Hopitaux de Paris, Paris, France.
| | - P G Steg
- FACT, French Alliance for Cardiovascular Trials, Département Hospitalo-Universitaire FIRE, Hôpital Bichat, Paris, France; INSERM U1148, LVTS, Paris, France; Imperial College, Royal Brompton Hospital, London, United Kingdom; Université de Paris, assistance publique-Hopitaux de Paris, Paris, France
| |
Collapse
|
10
|
Deharo P, Ducrocq G, Bode C, Cohen M, Cuisset T, Mehta SR, Pollack CV, Wiviott SD, Rao SV, Jukema JW, Erglis A, Moccetti T, Elbez Y, Steg PG. Blood transfusion and ischaemic outcomes according to anemia and bleeding in patients with non-ST-segment elevation acute coronary syndromes: Insights from the TAO randomized clinical trial. Int J Cardiol 2020; 318:7-13. [PMID: 32590084 DOI: 10.1016/j.ijcard.2020.06.020] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/10/2019] [Revised: 04/01/2020] [Accepted: 06/12/2020] [Indexed: 01/28/2023]
Abstract
BACKGROUND The benefits and risks of blood transfusion in patients with acute myocardial infarction who are anemic or who experience bleeding are debated. We sought to study the association between blood transfusion and ischemic outcomes according to haemoglobin nadir and bleeding status in patients with NST-elevation myocardial infarction (NSTEMI). METHODS The TAO trial randomized patients with NSTEMI and coronary angiogram scheduled within 72h to heparin plus eptifibatide versus otamixaban. After exclusion of patients who underwent coronary artery bypass surgery, patients were categorized according to transfusion status considering transfusion as a time-varying covariate. The primary ischemic outcome was the composite of all-cause death or MI within 180 days of randomization. Subgroup analyses were performed according to pre-transfusion hemoglobin nadir and bleeding status. RESULTS 12,547 patients were enrolled. Among these, blood transfusion was used in 489 (3.9%) patients. Patients who received transfusion had a higher rate of death or MI (29.9% vs. 8.1%, p<0.01). This excess risk persisted after adjustment on GRACE score and nadir of hemoglobin (HR 3.36 95%CI 2.63-4.29 p<0.01). Subgroup analyses showed that blood transfusion was associated with a higher risk in patients without overt bleeding (adjusted HR 6.25 vs. 2.85; p-interaction 0.001) as well as in those with hemoglobin nadir > 9.0 g/dl (HR 4.01; p-interaction<0.0001). CONCLUSION In patients with NSTEMI, blood transfusion was associated with an overall increased risk of ischaemic events. However, this was mainly driven by patients without overt bleeding and those hemoglobin nadir > 9.0g/dl. This suggests possible harm of transfusion in those groups.
Collapse
Affiliation(s)
- P Deharo
- Département de Cardiologie, CHU Timone, Marseille F-13385, France; Aix Marseille Univ, Inserm, Inra, C2VN, Marseille, France; Aix-Marseille Université, Faculté de Médecine, F-13385 Marseille, France
| | - G Ducrocq
- Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Paris, France; French Alliance for Cardiovascular Trials, Département Hospitalo-Universitaire FIRE, AP-HP, Hôpital Bichat, Université de Paris, Institut National de la Santé et de la Recherche Médicale, Paris, France
| | - C Bode
- Heart Center Freiburg University, Cardiology and Angiology I, Faculty of Medicine, Freiburg, Germany
| | - M Cohen
- Rutgers-New Jersey medical school, Newark, New Jersey, USA; Newark Beth Israel medical centre, Newark, New Jersey, USA
| | - T Cuisset
- Département de Cardiologie, CHU Timone, Marseille F-13385, France
| | - S R Mehta
- McMaster University and the Population Health Research Institute, Hamilton Health Sciences, Hamilton, Ontario, Canada
| | - C V Pollack
- Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
| | - S D Wiviott
- TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - S V Rao
- Department of Cardiology, Duke Clinical Research Institute, Durham, NC, USA
| | - J W Jukema
- Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands; The Netherlands Heart Institute, Utrecht, the Netherlands
| | - A Erglis
- University of Latvia, Pauls Stradins Clinical University Hospita, Riga, Latvia
| | - T Moccetti
- Electrophysiology Unit, Department of Cardiology, Fondazione Cardiocentro Ticino, via Tesserete 48, 6900 Lugano, Switzerland
| | - Y Elbez
- Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Paris, France; French Alliance for Cardiovascular Trials, Département Hospitalo-Universitaire FIRE, AP-HP, Hôpital Bichat, Université de Paris, Institut National de la Santé et de la Recherche Médicale, Paris, France
| | - P G Steg
- Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Paris, France; French Alliance for Cardiovascular Trials, Département Hospitalo-Universitaire FIRE, AP-HP, Hôpital Bichat, Université de Paris, Institut National de la Santé et de la Recherche Médicale, Paris, France; National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London, UK.
| |
Collapse
|
11
|
Langlais J, Urena M, Sonneville R, Verdonk C, Ou P, Ducrocq G, Bouadma L, Cimadevilla C, Dorent R, Nataf P, Himbert D. Percutaneous decompression of the left atrium to treat refractory pulmonary edema in patients supported by extracorporeal membrane oxygenation. Archives of Cardiovascular Diseases Supplements 2020. [DOI: 10.1016/j.acvdsp.2019.09.062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
12
|
Fuchs A, Urena Alcazar M, Nguyen C, Brochet E, Abtan J, Fischer Q, Ducrocq G, Iung B, Vahanian A, Himbert D. Transcatheter valve-in-valve or valve-in-ring mitral valve implantation in young women contemplating pregnancy. Archives of Cardiovascular Diseases Supplements 2020. [DOI: 10.1016/j.acvdsp.2019.09.163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
13
|
Danchin N, Puymirat E, Ducrocq G, Henry P, Collet JP, Genee O, Joseph T, Belle L, Naccache N, Ferrieres J, Schiele F, Simon T. P4569Differential prognostic impact of blood glucose levels at the acute stage of myocardial infarction according to HbA1c. The FAST-MI programme. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0959] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Hyperglycemia is a well-known prognostic marker in patients with acute myocardial infarction (AMI), associated with higher mortality compared with normoglycemia. Whether the prognostic impact of glycemic status at the acute stage of AMI is similar in patients with chronic dysglycemia has not been extensively explored.
Aims and methods
Using data from the nationwide French FAST-MI cohorts (2005, 2010 and 2015), we analysed the association between glycemia at entry and 30-day death, according to HbA1c level. From the 13,130 patients included, 5,452 had both glycemia and HbA1c assessed at entry. Of those, 1173 (21.5%) had an HbA1c ≥7%.
Results
In patients with HbA1c <7%, LVEF was inversely correlated with glycemic levels (55±11% for glycemia <100, 52±11% for glycemia 100–140, 50±12% for glycemia 140–160 and 49±12% for glycemia >180 mg/dl); a graded association between admission glycemia and 30-day mortality was observed, ranging from 0.7% in normoglycemic patients to 6.3% in patients with admission glycemia >180 mg/dl. In contrast, in patients with HbA1c ≥7%, LVEF was not correlated with glycemia (<100 mg/dl: 49±14%, >180 mg/dl 49±12%), and mortality was the highest in patients with normoglycemia (9.2%) and the lowest in patients with glycemia between 140 and 180 mg/dl (3.1%) (Figure). In multivariate analyses adjusting for baseline characteristics and early management, normoglycemia was associated with a decreased risk of 30-day mortality in patients with HbA1c <7% (HR 0.27, 95% confidence interval 0.10–0.73, P=0.01), while it was associated with a two-fold increase in mortality in patients with HbA1c ≥7% (HR 2.49, 95% confidence interval 1.02–6.09, P=0.046).
Figure 1. 30-day death
Conclusion
In AMI patients with high HbA1c levels on admission, normoglycemia is associated with higher early mortality than hyperglycemia. In contrast, a graded correlation is observed between admission glycemia and early mortality in patients with HbA1c <7%. Management of glycemia at the acute stage of MI might require different measures according to the initial HbA1c level.
Acknowledgement/Funding
Amgen, AstraZeneca, Bayer, Daiichi-Sankyo, Eli-Lilly, GSK, MSD, Novartis, Pfizer, Sanofi, Servier
Collapse
Affiliation(s)
- N Danchin
- AP-HP - European Hospital Georges Pompidou, Paris, France
| | - E Puymirat
- AP-HP - European Hospital Georges Pompidou, Paris, France
| | - G Ducrocq
- Hospital Bichat-Claude Bernard, Paris, France
| | - P Henry
- Hospital Lariboisiere, Paris, France
| | - J P Collet
- Hospital Pitie-Salpetriere, Paris, France
| | - O Genee
- Clinique de la Reine Blanche, Orleans, France
| | - T Joseph
- Centre Hospitalier, Quimper, France
| | - L Belle
- Hospital of Annecy, Annecy, France
| | - N Naccache
- French Society of Cardiology, Paris, France
| | - J Ferrieres
- Toulouse Rangueil University Hospital (CHU), Toulouse, France
| | - F Schiele
- Regional University Hospital Jean Minjoz, Besancon, France
| | - T Simon
- AP-HP - Hospital Saint Antoine, Paris, France
| |
Collapse
|
14
|
Dillinger JG, Ducrocq G, Elbez Y, Cohen M, Bode C, Pollack CJR, Petrauskiene B, Henry P, Dorobantu M, French WJ, Juliard JJ, Wiviott SD, Sabatine M, Mehta SD, Steg PG. P1694Sex is not an independent predictor of ischemic outcomes or bleeding in NSTEMI patients undergoing percutaneous coronary intervention. Insights from the TAO trial. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0449] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
There is uncertainty regarding whether female sex is an independent predictor of adverse outcomes in acute coronary syndromes (ACS).
Purpose
We sought to describe and compare ischemic and bleeding outcomes between men and women with Non–ST-segment–Elevation (NSTE) ACS enrolled in the large Treatment of Acute coronary syndromes with Otamixaban (TAO) trial in which antithrombotic treatment was standardized and a systematic invasive approach was performed.
Methods
The TAO trial randomized moderate to high-risk NSTE-ACS patients with diagnostic coronary angiography planned in the first 72 hours to heparin plus eptifibatide versus otamixaban. This post-hoc analysis describes ischemic (all-cause death, new myocardial infarction, stent thrombosis within 180 days of randomization) and bleeding outcomes (TIMI major and minor bleeding within 30 days of randomization) according to sex.
Results
Of 13,229 patients with NSTE-ACS randomized in 55 countries, 3,980 (30.1%) were female and 9,249 (69.9%) were male. Mean age was 64.8±11.0 and 60.7±11.1 years, respectively. The prevalence of diabetes (34.0% vs. 25.8%), hypertension (80.8% vs. 67.0%), and hypercholesterolemia (55.9% vs. 52.2%) was higher among women compared with men but current smoking (21.5% vs. 38.7%) and history of previous MI were more frequent in males (15.5% vs. 20.7%).
Females experienced a higher incidence of both ischemic outcomes (10.2% vs. 9.1%; OR=1.15; 95% CI, 1.01–1.30; p=0.034) and bleeding events (4.1% vs. 3.4%; OR=1.23; 95% CI, 1.02–1.49; p=0.029). Bleeding risk and CV death were particularly increased in women younger than 50 years, compared to males of the same age, at 5.5% vs. 1.4% (OR=4.00; 95% CI, 2.13–7.69; p=0.034) and 1.7% vs. 0.5% (OR=4.35; 95% CI, 1.02–20.00; p=0.02), respectively. No difference in either outcome was found between women and men between 50 and 80 years old. Above 80 years, women experienced a lower rate of bleeding (3.9% vs. 7.8%; OR=0.47; 95% CI, 0.23–0.88; p=0.024) but a similar rate of in ischemic events (16.0% vs. 17.2%; OR=0.92; 95% CI, 0.63–1.33; p=0.67).
After adjustment for age, body weight, diabetes mellitus, prior PCI, serum creatinine, presenting systolic blood pressure, elevated biomarker at presentation, heart failure, the risk of ischemic (OR=1.03; 95% CI, 0.89–1.18; p=0.71) and bleeding events (OR=1.05; 95% CI, 0.85–1.33; p=0.65) were similar between men and women.
Conclusions
In this large international randomized trial of NSTE-ACS with standardized invasive management, women (particularly those younger than 50 years) experienced higher risks of ischemic and bleeding events than men, but the difference was not sustained after adjustment. In this population, sex was not an independent predictor of adverse outcomes in NSTE-ACS. The type of ACS (NSTE-ACS) and routine invasive management in women and men may explain this absence of difference.
Acknowledgement/Funding
The TAO trial was sponsored and funded by SANOFI. The present analysis was supported by the RHU iVASC grant “#ANR-16-RHUS-00010”
Collapse
Affiliation(s)
- J.-G Dillinger
- Hospital Lariboisiere, Department of Cardiology, Paris, France
| | - G Ducrocq
- Hospital Bichat-Claude Bernard, Departement of cardiology, Paris, France
| | - Y Elbez
- Hospital Bichat-Claude Bernard, Departement of cardiology, Paris, France
| | - M Cohen
- Newark Beth Israel Medical Center, Department of Medicine, Newark, United States of America
| | - C Bode
- Medizinische Universitatsklinik, Freiburg, Germany
| | - C J R Pollack
- Thomas Jefferson University, Department of Emergency Medicine, Philadelphia, United States of America
| | - B Petrauskiene
- Vilnius University, Clinic of Cardiovascular Diseases, Vilnius, Lithuania
| | - P Henry
- Hospital Lariboisiere, Department of Cardiology, Paris, France
| | - M Dorobantu
- Emergency Clinical Hospital Floreasca, Department of Cardiology, Bucharest, Romania
| | - W J French
- Harbor-UCLA Medical Center, DHS Cardiology Workgroup, Torrance, United States of America
| | - J J Juliard
- Hospital Bichat-Claude Bernard, Departement of cardiology, Paris, France
| | - S D Wiviott
- Harvard Medical School, TIMI Study Group, Boston, United States of America
| | - M Sabatine
- Harvard Medical School, TIMI Study Group, Boston, United States of America
| | - S D Mehta
- McMaster University, Hamilton, Canada
| | - P G Steg
- Hospital Bichat-Claude Bernard, Departement of cardiology, Paris, France
| |
Collapse
|
15
|
Darmon A, Ducrocq G, Jasilek A, Juliard JM, Sorbets E, Ferrari R, Ford I, Tardif JC, Fox KM, Steg PG. 3294Frequency, management and outcomes of patients with stable coronary artery disease eligible for COMPASS. An analysis of the CLARIFY registry. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
Background
The COMPASS trial demonstrated that a combination of rivaroxaban and aspirin improved cardiovascular (CV) outcomes in high-risk patients with either peripheral artery disease (PAD) or stable coronary artery disease (CAD) compared with aspirin alone, at the price of increased bleeding. A previous analysis of the REACH Registry reported an eligibility rate of 52.9% within a population with stable vascular disease. However, most of cardiologists actually treat patients with stable CAD, rather than PAD. Data regarding eligibility to COMPASS in CAD patients from real life practice are scarce.
Purpose
We aimed to describe the proportion of patients eligible to COMPASS within the CLARIFY Registry. Additionally, we aimed to describe their management and outcomes, comparing patients excluded from the trial (COMPASS Excluded), patients eligible for the trial (COMPASS Eligible), and patients who did not meet the “enrichment criteria” for enrolment (COMPASS Not Included).
Methods
We used the CLARIFY Registry, an international observational registry of more than 30.000 patients with stable CAD. In accordance with COMPASS exclusion criteria, patients with a REACH bleeding risk score >10, heart failure (HF), severe renal insufficiency, need for dual antiplatelet therapy (DAPT), or anticoagulant (AC) therapy were excluded. Then, COMPASS inclusion criteria were applied: CAD patients had to be 65 years or more, or, if younger, have documented atherosclerosis (PAD or revascularization involving at least two vascular beds) or at least two enrichment criteria (current smoker, diabetes mellitus, GFR <60 mL/min, or non lacunar ischemic stroke).The ischemic outcome was a composite of CV death, MI, or stroke and bleeding outcome was a composite of bleeding leading to either admission or transfusion, or haemorrhagic stroke.
Results
Among 15.185 patients with comprehensive data allowing precise assessment of eligibility, 43.1% (n=6.540) had at least one exclusion criteria (COMPASS-Excluded), 23.1% (n=3.503) did not have enrichment criteria (COMPASS-Not Included) and 33.9% (n=5.142) were eligible. The vast majority of excluded patients were excluded due to high bleeding risk (62.7% needing DAPT, and 52.7% for high REACH bleeding risk score). The rates (100 patients/year) of ischemic and bleeding outcome were 2.3 [2.1–2.5] and 0.5 [0.4–0.6] respectively for COMPASS-Eligible, 3.0 [2.8–3.2] and 0.6 [0.5–0.7] for COMPASS-Excluded and 1.2 [1.0–1.4] and 0.2 [0.2–0.3] for COMPASS-Not Included.
Ischemic and bleeding events
Conclusion
In a large contemporary registry of stable CAD patients, approximately one of three patients was potentially eligible for adjunction of low-dose rivaroxaban to aspirin. This group is at particularly high risk of ischemic outcome. Patients with exclusion criteria for COMPASS had the worse ischemic and bleeding outcomes and represent a group in need of improved therapy.
Acknowledgement/Funding
None
Collapse
Affiliation(s)
- A Darmon
- Hospital Bichat-Claude Bernard, Cardiology, Paris, France
| | - G Ducrocq
- Hospital Bichat-Claude Bernard, Cardiology, Paris, France
| | - A Jasilek
- University of Glasgow, Robertson Center for Biostatistics, Glasgow, United Kingdom
| | - J M Juliard
- Hospital Bichat-Claude Bernard, Cardiology, Paris, France
| | - E Sorbets
- Hospital Avicenne of Bobigny, Université Paris 13, Bobigny, France
| | - R Ferrari
- Hospital Bichat-Claude Bernard, Cardiology, Paris, France
| | - I Ford
- University of Glasgow, Robertson Center for Biostatistics, Glasgow, United Kingdom
| | - J C Tardif
- Montreal Heart Institute, Montreal, Canada
| | - K M Fox
- Royal Brompton Hospital, NHLI Imperial College, ICMS, London, United Kingdom
| | - P G Steg
- Hospital Bichat-Claude Bernard, Cardiology, Paris, France
| |
Collapse
|
16
|
Darmon A, Ducrocq G, Jasliek A, Feldman LJ, Sorbets E, Ferrari R, Ford I, Tardif JC, Tendera M, Fox KM, Steg PG. P5010Use of risk score to identify lower and higher risk subsets among COMPASS-Eligible patients with stable CAD. Insights from the CLARIFY Registry. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0188] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
The COMPASS trial showed that a combination of rivaroxaban and aspirin improved cardiovascular (CV) outcomes in patients with stable coronary artery disease (CAD) compared with aspirin alone, at the expense of increased bleeding. An important issue is to identify in this broad population, patients who are likely to derive the greatest benefit without too great a bleeding risk.
Purpose
To evaluate the performance of the CHA2DS2VaSc (range from 0 to 9), the REACH Recurrent Ischemic Score (RIS) (range from 0 to ≥29) and the REACH Bleeding Risk Score (BRS) (range from 0 to 22) to identify patients with the most favourable trade-off between ischemic and bleeding events, among CAD patients eligible to COMPASS
Methods
We used the CLARIFY Registry, an international registry of >30.000 patients with stable CAD. COMPASS inclusion and exclusion criteria were applied to the CLARIFY population with complete data (n=15.185) to define the “COMPASS eligible population”. Patients at high bleeding risk (REACH BRS >10), were excluded in accordance to COMPASS exclusion criteria. Patients were categorized as low-intermediate (0–1) or high (≥2) CHA2DS2VaSc; low (0–12) or intermediate (13–19) REACH RIS, and low (0–6) or intermediate (7–10) REACH BRS. The ischemic outcome was a composite of CV death, MI or stroke, and the bleeding outcome was a composite of bleeding leading to either admission or transfusion, or haemorrhagic stroke.
Results
The COMPASS-eligible population comprised 5.142 patients (33.9%). Ischemic and bleeding outcome for this group were 2.3 [2.1–2.5] and 0.5 [0.4–0.6] events/100 patient-years, respectively. Patients with high CHA2DS2VaSc score, intermediate REACH BRS and RIS represented 95.5% (n=4.913), 83.8% (n=4.309) and 37.6% (n=1.934) of the population. Regarding ischemic risk, patients with intermediate REACH RIS had the higher ischemic risk (3.0 [2.6–3.4] vs 1.9 [1.7–2.1] for patients with low REACH RIS, p<0.001), followed by intermediate REACH BRS (2.5 [2.2–2.7] vs 1.5 [1.2–2.0] for patients with low REACH BRS, p=0.0003) and high CHA2DS2VaSc score (2.4 [2.2–2.6]), compared to the overall population. Patients with low CHA2DS2VaSc had the lowest ischemic risk (0.6 [0.3–1.3]) compared to the overall population. Regarding bleeding risk, there were no differences between patients categorized according to CHA2DS2VaSc (0.5 [0.2–1.15] vs 0.5 [0.4–0.6], p=0.95) REACH BRS (0.4 [0.3–0.7] vs 0.5 [0.4–0.6], p=0.80) or REACH RIS (0.4 [0.3–0.5] vs 0.5 [0.4–0.7], p=0.26).
Ischemic (blue) and bleeding (red) event
Conclusions
Among a broad population of CAD patients eligible to COMPASS, low CHA2DS2VaSc score identify a small subset of patients with very low ischemic risk which is unlikely to benefit from the adjunction of low dose rivaroxaban to standard therapy. Patients with intermediate REACH Recurrent Ischemic Score had higher ischemic risk, without increased bleeding risk and may be optimal candidates from adjunction of low dose rivaroxaban.
Acknowledgement/Funding
None
Collapse
Affiliation(s)
- A Darmon
- Hospital Bichat-Claude Bernard, Cardiology, Paris, France
| | - G Ducrocq
- Hospital Bichat-Claude Bernard, Cardiology, Paris, France
| | - A Jasliek
- University of Glasgow, Robertson Centre for Biostatistics, Glasgow, United Kingdom
| | - L J Feldman
- Hospital Bichat-Claude Bernard, Cardiology, Paris, France
| | - E Sorbets
- Hospital Avicenne of Bobigny, Université Paris 13, Bobigny, France
| | - R Ferrari
- Maria Cecilia Hospital, Department of Cardiology and LTTA Centre, University Hospital of Ferrara and Maria Cecilia Hospital,, Cotignola, Italy
| | - I Ford
- University of Glasgow, Robertson Centre for Biostatistics, Glasgow, United Kingdom
| | - J C Tardif
- Montreal Heart Institute, Montreal, Canada
| | - M Tendera
- Medical University of Silesia, Katowice, Poland
| | - K M Fox
- Royal Brompton Hospital, NHLI Imperial College, ICMS, London, United Kingdom
| | - P G Steg
- Hospital Bichat-Claude Bernard, Cardiology, Paris, France
| |
Collapse
|
17
|
Darmon A, Ducrocq G, Elbez Y, Sorbets E, Ferrari R, Ford I, Tardif JC, Tendera M, Fox KM, Steg PG. 2211Prevalence, incidence and prognostic implications of left bundle branch block in patients with stable coronary artery disease. an analysis from the CLARIFY registry. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
The prevalence, and prognostic implication of left bundle branch block (LBBB) in general population and patients admitted for acute myocardial infarction (MI) as been extensively studied. However, data are scarce about patients with stable coronary artery disease (CAD) and it remains unclear whether LBBB is only a marker of a severe cardiomyopathy or an independent predictor of events in these patients.
Purpose
We aimed to describe the prevalence, incidence and prognostic implications of LBBB in patients with stable CAD. Additionally, we aimed to describe the incidence of newly diagnosed LBBB that occurred without recent myocardial infarction.
Methods
CLARIFY is an international registry of more than 30.000 patients with stable CAD. LBBB was collected at baseline and at each follow-up visit, and patients were considered to have LBBB if the length of the QRS complex was of more than 120 milliseconds. Patients with previous pacemaker implantation of internal cardiac defibrillator were excluded. The primary outcome was a composite of cardiovascular (CV) Death, MI or stroke, and secondary outcomes included hospitalization for heart failure (HF) or the need for pacemaker implantation.
Results
From the 23.457 patients with available data regarding LBBB status, 1.041 (4.4%) had LBBB at baseline and 1.237 (5.3%) had at least one LBBB assessed during 5-year follow-up. Only 21 patients with newly diagnosed LBBB overtime, had a documented MI the same year. Compared to patients without LBBB, patients with LBBB had a higher risk profile regarding age (67.2±10.1 versus 63.6±10.4 years, p<0.0001), history of coronary artery bypass grafting (29.2% vs 23.7%, p<0.0001), diabetes (35.1% vs 28.4%, p<0.0001), and HF (25.2% vs 16.8%, p<0.0001) (Table). In unadjusted analysis, patients with LBBB had a higher risk of primary outcome (13.4% vs 8.7%, p<0.0001) and each secondary outcome. In multivariate analysis taking into account several possible confounders, there was no difference in the rate of CV death, MI or stroke between LBBB or no-LBBB patients (adjusted HR 1.04, 95% CI 0.85–1.29). However, patients with LBBB had a higher rate of pacemaker implantation (adjusted HR 2.21, 95% CI 1.55–3.15, p<0.0001) and hospitalization for HF (adjusted HR 1.53, 95% CI 1.25–1.88, p<0.0001) (Figure).
Outcomes according to LBBB status
Conclusion
The prevalence of LBBB in patients with stable CAD was 4.4% and 5.3% with 5-year follow-up. The overwhelming majority of newly diagnosed LBBB were not contemporary of documented myocardial infarction. LBBB was not associated with a higher rate of major adverse cardiovascular events, including all cause mortality but with a higher risk of pacemaker implantation and hospitalization for heart failure. To our knowledge this is the first study reporting such results in a broad population of stable CAD patients.
Acknowledgement/Funding
None
Collapse
Affiliation(s)
- A Darmon
- Hospital Bichat-Claude Bernard, Cardiology, Paris, France
| | - G Ducrocq
- Hospital Bichat-Claude Bernard, Cardiology, Paris, France
| | - Y Elbez
- Hospital Bichat-Claude Bernard, Cardiology, Paris, France
| | - E Sorbets
- Hospital Avicenne of Bobigny, Université Paris 13, Bobigny, France
| | - R Ferrari
- Maria Cecilia Hospital, Department of Cardiology and LTTA Centre, University Hospital of Ferrara and Maria Cecilia Hospital,, Cotignola, Italy
| | - I Ford
- University of Glasgow, Robertson Centre for Biostatistics, Glasgow, United Kingdom
| | - J C Tardif
- Montreal Heart Institute, University of Montreal, Montreal, Canada
| | - M Tendera
- Medical University of Silesia, Katowice, Poland
| | - K M Fox
- Royal Brompton Hospital, NHLI Imperial College, ICMS, London, United Kingdom
| | - P G Steg
- Hospital Bichat-Claude Bernard, Cardiology, Paris, France
| |
Collapse
|
18
|
Desnos C, Iung B, Himbert D, Ducrocq G, Cormier B, Brochet E, Vahanian A, Bouleti C. Temporal trends on percutaneous mitral commissurotomy: 30 years of experience. Archives of Cardiovascular Diseases Supplements 2019. [DOI: 10.1016/j.acvdsp.2019.02.148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
19
|
Desnos C, Iung B, Himbert D, Ducrocq G, Cormier B, Brochet E, Vahanian A, Bouleti C. Temporal trends on percutaneous mitral commissurotomy: 30 years of experience. Archives of Cardiovascular Diseases Supplements 2019. [DOI: 10.1016/j.acvdsp.2018.10.135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
20
|
Puymirat E, Iliou MC, Ducrocq G, Douard H, Labrunee M, Plastaras P, Chevalereau P, Taldir G, Bataille V, Ferrieres J, Schiele F, Simon T, Danchin N. P1231Clinical impact of cardiac rehabilitation according to the atherothrombotic risk stratification after acute myocardial infarction. The FAST-MI registries. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.p1231] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- E Puymirat
- European Hospital Georges Pompidou, Cardiology, Paris, France
| | - M C Iliou
- Corentin Celton Hospital APHP, Issy Les Moulineaux, France
| | - G Ducrocq
- Hospital Bichat-Claude Bernard, Paris, France
| | - H Douard
- Hospital Haut Leveque, Bordeaux-Pessac, France
| | - M Labrunee
- Toulouse Rangueil University Hospital (CHU), Toulouse, France
| | | | | | - G Taldir
- Centre Hospitalier, Saint-Brieuc, France
| | - V Bataille
- Toulouse Rangueil University Hospital (CHU), Toulouse, France
| | - J Ferrieres
- Toulouse Rangueil University Hospital (CHU), Toulouse, France
| | - F Schiele
- University of Besançon, Besançon, France
| | - T Simon
- Hospital Saint-Antoine, Paris, France
| | - N Danchin
- Hôpital Européen Georges Pompidou, Université Paris Descartes, Cardiology, Paris, France
| |
Collapse
|
21
|
Danchin N, Puymirat E, Roubille F, Silvain J, Ducrocq G, Soto F, De Poli F, Bataille V, Drouet E, Naccache N, Ferrieres J, Schiele F, Simon T. 6127Type of P2Y12 inhibitor at the acute stage and one-year mortality in acute myocardial infarction. The FAST-MI programme. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.6127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- N Danchin
- AP-HP - European Hospital Georges Pompidou, Paris, France
| | - E Puymirat
- AP-HP - European Hospital Georges Pompidou, Paris, France
| | - F Roubille
- University Hospital Arnaud de Villeneuve, Montpellier, France
| | - J Silvain
- Hospital Pitie-Salpetriere, Paris, France
| | - G Ducrocq
- Hospital Bichat-Claude Bernard, Paris, France
| | - F Soto
- Centre Hospitalier, Auxerre, France
| | - F De Poli
- Centre Hospitalier, Haguenau, France
| | - V Bataille
- Toulouse Rangueil University Hospital (CHU), Toulouse, France
| | - E Drouet
- AP-HP - Hospital Saint Antoine, Paris, France
| | - N Naccache
- French Society of Cardiology, Paris, France
| | - J Ferrieres
- Toulouse Rangueil University Hospital (CHU), Toulouse, France
| | - F Schiele
- Regional University Hospital Jean Minjoz, Besancon, France
| | - T Simon
- AP-HP - Hospital Saint Antoine, Paris, France
| | | |
Collapse
|
22
|
Puymirat E, Bonaca M, Cayla G, Lemesles G, Dillinger JG, Ducrocq G, Ferrieres J, Schiele F, Simon T, Danchin N. P5348Atherothrombotic risk stratification after acute myocardial infarction: the TIMI Risk Score for Secondary Prevention (TRS-2P) in the light of the FAST-MI registries. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p5348] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- E Puymirat
- European Hospital Georges Pompidou, Cardiology, Paris, France
| | - M Bonaca
- Harvard Medical School, Boston, United States of America
| | - G Cayla
- University Hospital of Nimes, Nimes, France
| | - G Lemesles
- Lille University Hospital, Lille, France
| | | | - G Ducrocq
- Hospital Bichat-Claude Bernard, Paris, France
| | - J Ferrieres
- Toulouse Rangueil University Hospital (CHU), Toulouse, France
| | - F Schiele
- Regional University Hospital Jean Minjoz, Besancon, France
| | - T Simon
- Hospital Saint-Antoine, Paris, France
| | - N Danchin
- European Hospital Georges Pompidou, Cardiology, Paris, France
| |
Collapse
|
23
|
Abtan J, Sorbets E, Popovic B, Elbez Y, Mehta S, Sabatine MS, Wiviott SD, Bode C, Pollack CV, Cohen M, Ducrocq G, Steg PG. P5106Prevalence, clinical characteristics and outcomes of procedural complications of percutaneous coronary intervention in non ST-elevation myocardial infarction: insights from the TAO trial. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p5106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- J Abtan
- Hospital Bichat-Claude Bernard, Paris, France
| | - E Sorbets
- Hospital Avicenne of Bobigny, Bobigny, France
| | - B Popovic
- Hospital Brabois of Nancy, Vandoeuvre les Nancy, France
| | - Y Elbez
- Hospital Bichat-Claude Bernard, Paris, France
| | - S Mehta
- McMaster University, Hamilton, Canada
| | - M S Sabatine
- Brigham and Women's Hospital, Boston, United States of America
| | - S D Wiviott
- Brigham and Women's Hospital, Boston, United States of America
| | - C Bode
- University of Freiburg, Freiburg, Germany
| | - C V Pollack
- Thomas Jefferson University Hospital, Philadelphia, United States of America
| | - M Cohen
- Newark Beth Israel Medical Center, Newark, United States of America
| | - G Ducrocq
- Hospital Bichat-Claude Bernard, Paris, France
| | - P G Steg
- Hospital Bichat-Claude Bernard, Paris, France
| |
Collapse
|
24
|
Popovic B, Sorbets E, Abtan J, Cohen M, Pollack C, Bode C, Wiviott SD, Sabatine M, Mehta SR, Elbez Y, Ducrocq G, Steg PG. P5537Clinical outcomes, mortality, and causes of death in patients with NSTEMI according to heart failure at admission: insights from a large contemporary revascularization trial. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p5537] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- B Popovic
- Hospital Brabois of Nancy, Vandoeuvre les Nancy, France
| | - E Sorbets
- Hospital Bichat-Claude Bernard, Paris, France
| | - J Abtan
- Hospital Bichat-Claude Bernard, Paris, France
| | - M Cohen
- Newark Beth Israel Medical Center, Newark, United States of America
| | - C Pollack
- Thomas Jefferson University Hospital, Philadelphia, United States of America
| | - C Bode
- University of Freiburg, Freiburg, Germany
| | - S D Wiviott
- Harvard Medical School, Boston, United States of America
| | - M Sabatine
- Harvard Medical School, Boston, United States of America
| | - S R Mehta
- Hamilton Health Sciences, Hamilton, Canada
| | - Y Elbez
- Hospital Bichat-Claude Bernard, Paris, France
| | - G Ducrocq
- Hospital Bichat-Claude Bernard, Paris, France
| | - P G Steg
- Hospital Bichat-Claude Bernard, Paris, France
| | | |
Collapse
|
25
|
Darmon A, Sorbets E, Ducrocq G, Elbez Y, Abtan J, Popovic B, Magnus Ohman E, Rother J, Wilson PWF, Montalescot G, Zeymer U, Bhatt DL, Steg PG. 5262Identifying higher risk patients among the COMPASS-Eligible population: An analysis from the REduction of atherothrombosis for continued health (REACH) Registry. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.5262] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- A Darmon
- Hospital Bichat-Claude Bernard, FACT, Department of Cardiology, Paris, France
| | - E Sorbets
- Hospital Avicenne of Bobigny, Université Paris 13, Bobigny, France
| | - G Ducrocq
- Hospital Bichat-Claude Bernard, FACT, Department of Cardiology, Paris, France
| | - Y Elbez
- Hospital Bichat-Claude Bernard, Cardiology, Paris, France
| | - J Abtan
- Hospital Bichat-Claude Bernard, FACT, Department of Cardiology, Paris, France
| | - B Popovic
- Hospital Brabois of Nancy, University Hospital of Nancy, Vandoeuvre les Nancy, France
| | - E Magnus Ohman
- Duke University Medical Center, Division of Cardiovascular Medicine, Durham, United States of America
| | - J Rother
- Asklepios Clinic Altona, Department of Neurology, Hamburg, Germany
| | - P W F Wilson
- Emory University School of Medicine, Medical Center and Cardiology Division, Atlanta, United States of America
| | - G Montalescot
- Hospital Pitie-Salpetriere, ACTION Study Group, Department of Cardiology, Paris, France
| | - U Zeymer
- Klinikum Ludwigshafen, Ludwigshafen Am Rhein, Germany
| | - D L Bhatt
- Brigham and Women's Hospital, Harvard Medical School, Boston, United States of America
| | - P G Steg
- Hospital Bichat-Claude Bernard, FACT, Department of Cardiology, Paris, France
| | | |
Collapse
|
26
|
Barbieux P, György B, Gand E, Saulnier PJ, Ducrocq G, Halimi JM, Feigerlova E, Hulin-Delmotte C, Llaty P, Montaigne D, Rigalleau V, Roussel R, Sosner P, Zaoui P, Ragot S, Marre M, Tregouët DA, Hadjadj S. No prognostic role of a GWAS-derived genetic risk score in renal outcomes for patients from French cohorts with type 1 and type 2 diabetes. Diabetes Metab 2018. [PMID: 29540294 DOI: 10.1016/j.diabet.2018.01.016] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Affiliation(s)
- P Barbieux
- Service d'endocrinologie, CHU de Poitiers, 86000 Poitiers, France
| | - B György
- Inserm UMR-S1166, Sorbonne universités, UPMC université Paris 06, 75013, Paris, France; ICAN Institute for Cardiometabolism and Nutrition, 75013 Paris, France
| | - E Gand
- CHU de Poitiers, pôle Dune, 86000 Poitiers, France
| | - P-J Saulnier
- UFR médecine pharmacie, centre d'investigation clinique, université de Poitiers, 86000 Poitiers, France; CHU de Poitiers, centre d'investigation clinique, 86000 Poitiers, France; Inserm, CIC 1402 & U1082, 86000 Poitiers, France
| | - G Ducrocq
- Inserm U698, 75018 Paris, France; Département de cardiologie, groupe hospitalier Bichat Claude-Bernard, Assistance publique-Hôpitaux de Paris (AP-HP), 75018 Paris, France
| | - J-M Halimi
- Service néphrologie, dialyse et transplantation, CHU de Tours, 37000 Tours, France; Inserm, centre d'investigation clinique 0202, 37000 Tours, France
| | - E Feigerlova
- Service d'endocrinologie, CHU de Poitiers, 86000 Poitiers, France; UFR médecine pharmacie, centre d'investigation clinique, université de Poitiers, 86000 Poitiers, France; CHU de Poitiers, centre d'investigation clinique, 86000 Poitiers, France; Inserm, CIC 1402 & U1082, 86000 Poitiers, France
| | | | - P Llaty
- Service de cardiologie, CHU de Poitiers, 86000 Poitiers, France
| | - D Montaigne
- Service d'explorations fonctionnelles cardiovasculaires, CHU de Lille, 59000 Lille, France; Université de Lille, 59000 Lille, France; Inserm, U1011, 59000 Lille, France; EGID, 59000 Lille, France; Institut Pasteur de Lille, 59019 Lille, France
| | - V Rigalleau
- Service endocrinologie, diabétologie maladies métaboliques et nutrition, CHU de Bordeaux, 33604 Pessac cedex, France; Université Victor-Segalen, faculté de médecine, 33000 Bordeaux, France
| | - R Roussel
- UMR_S 1138, centre de recherche des Cordeliers, Sorbonne Paris-Cité, université Paris-Diderot, 75006 Paris, France; Diabetologie endocrinologie nutrition, DHU FIRE, AP-HP, hôpital Bichat, 75018 Paris, France; Inserm UMR-S 1138, centre de recherche des Cordeliers, 75006 Paris, France
| | - P Sosner
- Service de cardiologie, CHU de Poitiers, 86000 Poitiers, France; Complexe médico-sportif Mon Stade, 75013 Paris, France; Laboratoire MOVE (EA 6314), université de Poitiers, 86000 Poitiers, France
| | - P Zaoui
- Service néphrologie, dialyse et transplantation, CHU de Grenoble, 38000 Grenoble, France; Faculté de médecine, université Grenoble Alpes, 38000 Grenoble, France
| | - S Ragot
- UFR médecine pharmacie, centre d'investigation clinique, université de Poitiers, 86000 Poitiers, France; CHU de Poitiers, centre d'investigation clinique, 86000 Poitiers, France; Inserm, CIC 1402 & U1082, 86000 Poitiers, France
| | - M Marre
- UMR_S 1138, centre de recherche des Cordeliers, Sorbonne Paris-Cité, université Paris-Diderot, 75006 Paris, France; Diabetologie endocrinologie nutrition, DHU FIRE, AP-HP, hôpital Bichat, 75018 Paris, France; Inserm UMR-S 1138, centre de recherche des Cordeliers, 75006 Paris, France
| | - D-A Tregouët
- Inserm UMR-S1166, Sorbonne universités, UPMC université Paris 06, 75013, Paris, France; ICAN Institute for Cardiometabolism and Nutrition, 75013 Paris, France
| | - S Hadjadj
- Service d'endocrinologie, CHU de Poitiers, 86000 Poitiers, France; UFR médecine pharmacie, centre d'investigation clinique, université de Poitiers, 86000 Poitiers, France; CHU de Poitiers, centre d'investigation clinique, 86000 Poitiers, France; Inserm, CIC 1402 & U1082, 86000 Poitiers, France; UFR médecine pharmacie, université de Poitiers, 86000 Poitiers, France.
| | | | | |
Collapse
|
27
|
Hyafil F, Chequer R, Sorbets E, Ducrocq G, Abtan J, Rouzet F, Marie P, Le Guludec D. Higher diagnostic performances of 82Rubidium-PET in comparison to SPECT myocardial perfusion scintigraphy for the detection of patients with three-vessel coronary artery disease. Archives of Cardiovascular Diseases Supplements 2018. [DOI: 10.1016/j.acvdsp.2017.11.318] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
28
|
Puymirat E, Roussel R, Aissaoui N, Ducrocq G, Ferrari E, Legros G, Lemesle G, Marcaggi X, Belle L, Ferrieres J, Schiele F, Simon T, Danchin N. 2187Long-term prognostic significance of diabetes mellitus according to renal function in myocardial infarction patients. The FAST-MI 2005 registry. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx502.2187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- E. Puymirat
- AP-HP - European Hospital Georges Pompidou, Paris, France
| | - R. Roussel
- Hospital Bichat-Claude Bernard, Paris, France
| | - N. Aissaoui
- AP-HP - European Hospital Georges Pompidou, Paris, France
| | - G. Ducrocq
- Hospital Bichat-Claude Bernard, Paris, France
| | - E. Ferrari
- University Hospital Pasteur of Nice, Nice, France
| | | | | | | | - L. Belle
- Hospital of Annecy, Annecy, France
| | - J. Ferrieres
- Toulouse Rangueil University Hospital (CHU), Toulouse, France
| | - F. Schiele
- Regional University Hospital Jean Minjoz, Besancon, France
| | - T. Simon
- AP-HP - Hospital Saint Antoine, Paris, France
| | - N. Danchin
- AP-HP - European Hospital Georges Pompidou, Paris, France
| | | |
Collapse
|
29
|
Hyafil F, Chequer R, Sorbets E, Estellat C, Rouzet F, Ducrocq G, Abtan J, Touati A, Alfaiate T, Leygnac S, Milliner M, Ben Azzouna R, Hartemann A, Roussel R, Montalescot G, Marie P, Le Guludec D. High diagnostic performances of 82 Rubidium-PET for the detection of coronary artery disease as compared to 99 Tc-MIBI with CZT gamma cameras in a population of overweighed patients and women. Archives of Cardiovascular Diseases Supplements 2017. [DOI: 10.1016/s1878-6480(17)30163-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
30
|
Ducrocq G, Nejjari M, Juliard JM. Prise en charge en 2014 des syndromes coronaires aigus avec sus-décalage du segment ST. Réanimation 2014. [DOI: 10.1007/s13546-014-0852-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
31
|
Ducrocq G, Bhatt DL, Labreuche J, Corbalan R, Porath A, Gao R, Panchenko E, Liau CS, Ikeda Y, Goto S, Amarenco P, Steg PG. Geographic differences in outcomes in outpatients with established atherothrombotic disease: results from the REACH Registry. Eur J Prev Cardiol 2013; 21:1509-16. [DOI: 10.1177/2047487313501278] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Affiliation(s)
- G Ducrocq
- Université Paris-Diderot, Sorbonne Paris Cité, France; AP-HP, Hopital Bichat - Paris, France; INSERM U-698, France
| | - DL Bhatt
- VA Boston Healthcare System, Brigham and Women’s Hospital, Harvard Medical School, USA
| | - J Labreuche
- Université Paris-Diderot, Sorbonne Paris Cité, France; AP-HP, Hopital Bichat - Paris, France; INSERM U-698, France
| | - R Corbalan
- Pontificia Universidad Católica de Chile, Chile
| | - A Porath
- Department of Epidemiology, Ben-Gurion University of the Negev, Israel
| | - R Gao
- Cardiovascular Institute & Fuwai Hospital, People's Republic of China
| | - E Panchenko
- Cardiology Research Center, Russian Federation, Russia
| | - CS Liau
- National Taiwan University Hospital, Taiwan
| | - Y Ikeda
- Kokura Memorial Hospital, Japan
| | | | - P Amarenco
- Université Paris-Diderot, Sorbonne Paris Cité, France; AP-HP, Hopital Bichat - Paris, France; INSERM U-698, France
| | - PG Steg
- Université Paris-Diderot, Sorbonne Paris Cité, France; AP-HP, Hopital Bichat - Paris, France; INSERM U-698, France
| |
Collapse
|
32
|
Puymirat E, Ducrocq G. [Comparison between European Society of Cardiology (ESC) and American College of Cardiology/American Heart Association (ACC/AHA) guidelines for initial management of ST-elevation myocardial infarction (STEMI)]. Ann Cardiol Angeiol (Paris) 2013; 62:265-8. [PMID: 23916786 DOI: 10.1016/j.ancard.2013.06.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2013] [Accepted: 06/12/2013] [Indexed: 10/26/2022]
Abstract
The European Society of Cardiology (ESC) and American College of Cardiology/American Heart Association (ACC/AHA) have recently updated guidelines for management of ST-elevation myocardial infarction (STEMI). The aim of this study is to compare the both recommendations.
Collapse
Affiliation(s)
- E Puymirat
- Department of Cardiology, hôpital européen Georges-Pompidou, Assistance publique-Hôpitaux de Paris (AP-HP), 20, rue Leblanc, 75015 Paris, France; Université Paris-Descartes, 75006 Paris, France; Inserm U-970, 75015 Paris, France.
| | | |
Collapse
|
33
|
Ducrocq G, Puymirat E, Danchin N, Henry P, Martelet M, Ennezat PV, Schiele F, Steg PG, Ferrieres J, Simon T. Blood transfusion per se does not impact survival in AMI patients. A propensity-score analysis from the French FAST-MI 2005 registry. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht307.p414] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
34
|
Fassa AA, Himbert D, Brochet E, Iung B, Ducrocq G, Nejjari M, Depoix JP, Nataf P, Vahanian A. Transfemoral implantation of percutaneous heart valves following atrioventricular bioprosthesis and ring annuloplasty failure. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht308.p2158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
35
|
Mansencal N, Gerbaud E, Doyen D, Lesavre N, Donal E, Motreff P, Meimoun P, Ducrocq G, Nallet O, Founier A, Ederhy S, Lamblin N, Varenne O, Probst V, Ihaddaden M, Aupetit F, Dubourg O. Assessment of initial left ventricular systolic dysfunction in Tako-Tsubo cardiomyopathy by multimodality imaging. Arch Cardiovasc Dis 2013. [DOI: 10.1016/j.acvd.2013.03.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
36
|
Ducrocq G, Bigard MA, Marouene S, Delaage PH, Fabry C, Barthelemy P, Steg PG. [Risk factors of upper gastrointestinal complications in outpatients on antiplatelet therapy: description and management]. Ann Cardiol Angeiol (Paris) 2012; 61:245-51. [PMID: 22579299 DOI: 10.1016/j.ancard.2012.01.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2011] [Accepted: 01/26/2012] [Indexed: 10/28/2022]
Abstract
OBJECTIVES Patients on antiplatelet therapy have a gastrointestinal bleeding risk. It is increased by risk factors. The frequency of those risk factors, the prevalence of upper digestive symptoms and their management in patients on antiplatelet agents is unknown. PATIENTS AND METHODS We performed an observational multi-centred prospective survey among 560 French cardiologists with private practice. Each cardiologist completed a questionnaire for the first four patients treated with antiplatelet agents in primary or secondary prevention. RESULTS Among the 2182 patients included, (age = 67 ± 11 years; 74% male), 83% had at least one gastrointestinal bleeding risk factor and 38.9% had a history of upper digestive tract symptom. A history of gastrointestinal bleeding was reported in 3.4% and a history of documented gastro-duodenal ulcer in 5.5%. A proton pump inhibitor was already prescribed in 39% of the patients. At the time of the consultation, upper digestive symptoms were described in 21% of the patients. In those patients with symptoms, 85% had no modification in antiplatelet therapy and 62.7% were prescribed gastro-protective drugs (proton pump inhibitors: 51.8%, H(2)-blockers 3.6% other anti-acid medication: 7.3%). CONCLUSION Among patients on antiplatelet agents, the prevalence of upper digestive symptoms and risk factors for gastrointestinal bleeding is high. Preventative management needs to be clarified in this population.
Collapse
Affiliation(s)
- G Ducrocq
- Inserm U698, recherche clinique en athérothrombose, service de cardiologie, centre hospitalier Bichat Claude-Bernard, université Paris-Diderot, 46, rue Henri-Huchard, 75018 Paris, France.
| | | | | | | | | | | | | | | |
Collapse
|
37
|
Vergès B, Avignon A, Bonnet F, Catargi B, Cattan S, Cosson E, Ducrocq G, Elbaz M, Fredenrich A, Gourdy P, Henry P, Lairez O, Leguerrier A, Monpère C, Moulin P, Vergès-Patois B, Roussel R, Steg G, Valensi P. Consensus statement on the care of the hyperglycaemic/diabetic patient during and in the immediate follow-up of acute coronary syndrome. Diabetes & Metabolism 2012; 38:113-27. [DOI: 10.1016/j.diabet.2011.11.003] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/23/2011] [Accepted: 11/24/2011] [Indexed: 01/19/2023]
|
38
|
Pham QH, Von Lueder TG, Namtvedt SK, Rosjo H, Omland T, Steine K, Timoteo AT, Mota Carmo M, Simoes M, Branco LM, Ferreira RC, Kato R, Ito J, Tahara T, Yokoyama Y, Ashikaga T, Satoh Y, Na JO, Hong HE, Kim MN, Shin SY, Choi CU, Kim EJ, Rha SW, Park CG, Seo HS, Oh DJ, Ticulescu R, Brigido S, Vriz O, Sparacino L, Popescu BA, Ginghina C, Carerj S, Nicolosi GL, Antonini-Canterin F, Onaindia Gandarias JJ, Romero A, Laraudogoitia E, Velasco S, Quintana O, Cacicedo A, Rodriguez I, Alarcon JA, Gonzalez J, Lekuona I, Onaindia Gandarias JJ, Laraudogoitia E, Romero A, Velasco S, Cacicedo A, Quintana O, Subinas A, Gonzalez J, Alarcon JA, Lekuona I, Abdula G, Lund LH, Winter R, Brodin L, Sahlen A, Masaki M, Cha YM, Yuasa T, Dong K, Dong YX, Mankad SV, Oh JK, Vallet F, Lequeux B, Diakov C, Sosner P, Christiaens L, Coisne D, Kihara C, Murata K, Wada Y, Uchida K, Ueyama T, Okuda S, Susa T, Matsuzaki M, Cho EJ, Choi KY, Kwon BJ, Kim DB, Jang SW, Cho JS, Jung HO, Jeon HK, Youn HJ, Kim JH, Cikes M, Bijnens B, Velagic V, Kopjar T, Milicic D, Biocina B, Gasparovic H, Almuntaser I, Brown A, Foley B, Mulvihill N, Crean P, King G, Murphy R, Takata Y, Taniguchi M, Nobusada S, Sugawara M, Toh N, Kusano K, Itoh H, Wellnhofer E, Kriatselis C, Nedios S, Gerds-Li JH, Fleck E, Poulsen MK, Henriksen JE, Dahl J, Johansen A, Haghfelt T, Hoilund-Carlsen PF, Beck-Nielsen H, Moller JE, Dankowski R, Wierzchowiecki M, Michalski M, Nowicka A, Szymanowska K, Pajak A, Poprawski K, Szyszka A, Kasner M, Westermann D, Schultheiss HP, Tschoepe C, Watanabe T, Iwai-Takano M, Kobayashi A, Machii H, Takeishi Y, Paelinck BP, Van Herck PL, Bosmans JM, Vrints CJ, Lamb HJ, Doltra A, Vidal B, Silva E, Poyatos S, Mont L, Berruezo A, Castel A, Tolosana JM, Brugada J, Sitges M, Dencker M, Bjorgell O, Hlebowicz J, Szelenyi ZS, Szenasi G, Kiss M, Prohaszka Z, Patocs A, Karadi I, Vereckei A, Saha SK, Anderson PL, Govind S, Govindan M, Moggridge JC, Kiotsekoglou A, Gopal AS, Loegstrup BB, Christophersen TB, Hoefsten DE, Moeller JE, Boetker HE, Egstrup K, Wellnhofer E, Kriatselis C, Nedios S, Gerds-Li JH, Fleck E, Graefe M, Huang FQ, Zhang RS, Le TT, Tan RS, Sattarzadeh Badkoubeh R, Tavoosi A, Elahian AR, Drapkina O, Ivashkin VI, Vereckei A, Szelenyi ZS, Fazakas A, Pepo L, Janosi O, Karadi I, Kopitovic I, Goncalves A, Marcos-Alberca P, Almeria C, Feltes G, Rodriguez E, Garcia E, Hernandez-Antolin R, Macaya C, Silva Cardoso J, Zamorano JL, Navarro MS, Valentin M, Banes CM, Rigo F, Grolla E, Tona F, Cuaia V, Moreo A, Badano L, Raviele A, Iliceto S, Tarzia P, Sestito A, Nerla R, Di Monaco A, Infusino F, Matera D, Greco F, Tacchino RM, Lanza GA, Crea F, Nemes A, Balazs E, Pinter KS, Egyed A, Csanady M, Forster T, Loegstrup BB, Christophersen TB, Hoefsten DE, Moeller JE, Boetker HE, Egstrup K, Holte E, Vegsundvag J, Hole T, Hegbom K, Wiseth R, Nemes A, Balazs E, Pinter KS, Egyed A, Csanady M, Forster T, Sharif D, Sharif-Rasslan A, Shahla C, Khalil A, Rosenschein U, Zagatina A, Zhuravskaya N, Tyurina TV, Tagliamonte E, Cirillo T, Coppola A, Marinelli U, Romano C, Riccio G, Citro R, Astarita C, Capuano N, Tagliamonte E, Cirillo T, Marinelli U, Quaranta G, Desiderio A, Riccio G, Romano C, Capuano N, Frattini S, Faggiano P, Zilioli V, Locantore E, Longhi S, Bellandi F, Faden G, Triggiani M, Dei Cas L, Dalsgaard M, Kjaergaard J, Iversen K, Hassager C, Dinh W, Nickl WN, Smettan JS, Koehler TK, Scheffold TD, Coll Barroso MCB, Guelker JG, Fueth RF, Kamperidis V, Hadjimiltiades S, Sianos G, Efthimiadis G, Karvounis H, Parcharidis G, Styliadis IH, Velasco Del Castillo MS, Cacicedo A, Onaindia JJ, Quintana O, Alarcon JA, Rodriguez I, Telleria M, Subinas A, Lekuona I, Laraudogoitia E, Carstensen HG, Nordenberg C, Sogaard P, Fritz-Hansen T, Bech J, Galatius S, Jensen JS, Mogelvang R, Bartko PE, Graf S, Rosenhek R, Burwash IG, Bergler-Klein J, Clavel MA, Baumgartner H, Pibarot P, Mundigler G, Kirilmaz B, Eser I, Tuzun N, Komur B, Dogan H, Taskiran Comez A, Ercan E, Cusma-Piccione M, Zito C, Oreto G, Piluso S, Tripepi S, Oreto L, Longordo C, Ciraci L, Di Bella G, Carerj S, Piatkowski R, Kochanowski J, Scislo P, Grabowski M, Marchel M, Roik M, Kosior D, Opolski G, Sknouril L, Dorda M, Holek B, Gajdusek L, Chovancik J, Branny M, Fiala M, Szymanski P, Lipczynska M, Klisiewicz A, Hoffman P, Jander N, Minners J, Martin G, Zeh W, Allgeier M, Gohlke-Baewolf C, Gohlke H, Nistri S, Porciani MC, Attanasio M, Abbate R, Gensini GF, Pepe G, Duncan RF, Piantadosi C, Nelson AJ, Wittert G, Dundon B, Worthley MI, Worthley SG, Jung P, Berlinger K, Rieber J, Sohn HZ, Schneider P, Leibig M, Koenig A, Klauss V, Tomkiewicz-Pajak L, Kolcz J, Olszowska M, Pieculewicz M, Podolec P, Pieculewicz M, Przewlocki T, Tomkiewicz-Pajak L, Suchon E, Sobien B, Podolec P, Pieculewicz M, Przewlocki T, Wilkolek P, Tomkiewicz-Pajak L, Ziembicka A, Podolec P, Pieculewicz M, Przewlocki T, Tomkiewicz-Pajak L, Hlawaty M, Wilkolek P, Sobien B, Suchon E, Podolec P, Van De Bruaene A, Hermans H, Buys R, Vanhees L, Delcroix M, Voigt JU, Budts W, De Cillis E, Acquaviva T, Basile D, Bortone AS, Kalimanovska-Ostric D, Nastasovic T, Vujisic-Tesic B, Jovanovic I, Milakovic B, Dostanic M, Stosic M, Frogoudaki A, Andreou K, Parisis J, Triantafyllidi E, Gaitani S, Paraskevaidis J, Anastasiou-Nana M, Pieculewicz M, Przewlocki T, Tomkiewicz-Pajak L, Sobien B, Hlawaty M, Podolec P, De Pasquale G, Kuehn A, Petzuch K, Mueller J, Meierhofer C, Fratz S, Hager A, Hess J, Vogt M, Attenhofer Jost CH, Dearani JA, Scott CG, Burkhart HM, Connolly HM, Vitarelli A, Battaglia D, Caranci F, Padella V, Continanza G, Dettori O, Capotosto L, Vitarelli M, De Cicco V, Cortez Morichetti M, Mohanan Nair KK, Sasidaharan B, Thajudeen A, Tharakan JM, Mertens L, Ahmad N, Kantor PK, Grosse-Wortmann L, Friedberg MK, Bernard YF, Morel MA, Descotes-Genon V, Jehl J, Meneveau N, Schiele F, Kaldararova M, Simkova I, Tittel P, Masura J, Trojnarska O, Szczepaniak L, Mizia -Stec K, Cieplucha A, Bartczak A, Grajek S, Tykarski A, Gasior Z, Attenhofer Jost CH, Babovicvuksanovic D, Scott CG, Bonnichsen CR, Burkhart HM, Connolly HM, Morgan GJ, Slorach C, Hui W, Sarkola T, Lee KJ, Chaturvedi R, Benson L, Mertens L, Bradley T, Iancu ME, Ghiorghiu I, Serban M, Craciunescu I, Hodo A, Popescu BA, Ginghina C, Morgan J, Morgan GJ, Slorach C, Hui W, Roche L, Lee K, Chaturvedi R, Benson L, Bradley T, Mertens L, Morgan J, Morgan GJ, Slorach C, Hui W, Sarkola T, Lee K, Chaturvedi R, Benson L, Bradley T, Mertens L, Milanesi O, Favero V, Padalino M, Biffanti R, Cerutti A, Maschietto N, Reffo E, Vida V, Stellin G, Irtyuga O, Gamazin D, Voronkina I, Tsoyi N, Gudkova E, Moiseeva O, Aggeli C, Kazazaki C, Felekos I, Lagoudakou S, Roussakis G, Skoumas J, Pitsavos C, Stefanadis C, Cueff C, Keenan N, Steg PG, Cimadevilla C, Ducrocq G, Vahanian A, Messika-Zeitoun D, Petrella L, Mazzola AM, Villani CV, Giancola RG, Ciocca MC, Di Eusanio DEM, Nolan S, Ionescu A, Skaug TR, Amundsen BH, Hergum T, Torp H, Haugen BO, Lopez Aguilera J, Mesa Rubio D, Ruiz Ortiz M, Delgado Ortega M, Villanueva Fernandez E, Cejudo Diaz Del Campo L, Toledano Delgado F, Leon Del Pino M, Romo Pena E, Suarez De Lezo Cruz-Conde J, De Marco E, Colucci A, Comerci G, Gabrielli FA, Natali R, Garramone B, Savino M, Lotrionte M, Sonaglioni A, Loperfido F, Zdravkovic M, Perunicic J, Krotin M, Ristic M, Vukomanovic V, Zaja M, Radovanovic S, Saric J, Zdravkovic D, Cotrim C, Almeida AR, Miranda R, Almeida AG, Picano E, Carrageta M, D'andrea A, Cocchia R, Riegler L, Golia E, Scarafile R, Citro R, Caso P, Russo MG, Bossone E, Calabro' R, Noman H, Adel A, Elfaramawy AMR, Abdelraouf M, Elnaggar WAEL, Baligh E, Sargento L, Silva D, Goncalves S, Ribeiro S, Vinhas Sousa G, Almeida A, Lopes M, Rodriguez-Manero M, Aguado Gil L, Azcarate P, Lloret Luna P, Macias Gallego A, Castano SARA, Garcia M, Pujol Salvador C, Barba J, Redondo P, Tomasoni L, Sitia S, Atzeni F, Gianturco L, Ricci C, Sarzi-Puttini P, Turiel M, Sitia S, Tomasoni L, Atzeni F, De Gennaro Colonna V, Sarzi-Puttini P, Turiel M, Uejima T, Jaroch J, Antonini-Canterin F, Polombo C, Carerj S, Hughes A, Vinereanu D, Evanvelista A, Leftheriotis G, Fraser AG, Lewczuk A, Sobkowicz B, Tomaszuk-Kazberuk A, Sawicki R, Hirnle T, Michalski BW, Filipiak D, Kasprzak JD, Lipiec P, Dalen H, Haugen BO, Mjolstad OC, Klykken BE, Graven T, Martensson M, Olsson M, Brodin LA, Antonini-Canterin F, Ticulescu R, Vriz O, Enache R, Leiballi E, Popescu BA, Ginghina C, Nicolosi GL, Penhall A, Perry R, Altman M, Sinhal A, Bennetts J, Chew DP, Joseph MX, Larsen LH, Kjaergaard J, Kristensen T, Kober LV, Kofoed KF, Hassager C, Moscoso Costa F, Ribeiras R, Brito J, Boshoff S, Neves J, Teles R, Canada M, Andrade MJ, Gouveia R, Silva A, Miskovic A, Poerner TP, Stiller CS, Goebel BG, Moritz AM, Stefani L, Galanti GG, Moraldo M, Bergamini C, Pabari PA, Dhutia NM, Malaweera ASN, Willson K, Davies J, Hughes AD, Xu XY, Francis DP, Jasaityte R, Amundsen B, Barbosa D, Loeckx D, Kiss G, Orderud F, Robesyn V, Claus P, Torp H, D'hooge J, Kihara C, Murata K, Wada Y, Uchida K, Nao T, Okuda S, Susa T, Miura T, Matsuzaki M, Shams K, Samir S, Samir R, El-Sayed M, Anwar AM, Nosir Y, Galal A, Chamsi-Pasha H, Ciobanu A, Dulgheru R, Bennett S, Vinereanu D, De Luca A, Toncelli L, Cappelli F, Stefani L, Cappelli B, Vono MCR, Galanti G, Zorman Y, Yilmazer MS, Akyildiz M, Gurol T, Aydin A, Dagdeviren B, Kalangos A. Poster session V * Saturday 11 December 2010, 08:30-12:30. European Journal of Echocardiography 2010. [DOI: 10.1093/ejechocard/jeq148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
39
|
Steg PG, Ducrocq G. Devices to protect against embolization during primary angioplasty for ST-segment elevation myocardial infarction: the good, the bad and the ugly. Eur Heart J 2008; 29:2953-4. [DOI: 10.1093/eurheartj/ehn488] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
40
|
Paradis JM, Ducrocq G, Tanguay JF. Antiplatelet therapy following drug-eluting stent implantation: new clinical data and recommendations. Minerva Cardioangiol 2008; 56:139-154. [PMID: 18432176] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
Technological developments in percutaneous coronary interventions (PCI) allow the possibility for less invasive revascularization in an increasing number of patients with atherosclerotic coronary artery disease. Bare-metal stents (BMS) have considerably improved the efficacy of PCI in addition to greatly reducing restenosis. However, even with standard stents, restenosis has remained a significant limitation of this revascularization technique. The advent of drug-eluting stents (DES) has dramatically reduced in-stent restenosis and, as a result, the need for repeat revascularization. However, their potential thrombogenicity has raised concerns about their clinical utility and long-term safety. Indeed, there is a possible higher rate of late stent thrombosis (LST) with DES compared with BMS. Antiplatelet therapy has been shown to be efficient in preventing DES thrombosis. Nevertheless, in the future, significant improvement will occur to improve the safety and efficacy of this therapy. This article will summarize the pathophysiology and the epidemiology of stent thrombosis (ST). Definitions of definite, probable and possible ST will be described. Furthermore, clinical risk factors for ST will be clearly enumerated. Then, the various antiplatelet therapeutic strategies used to prevent ST will be taken in consideration. Finally, a summary of the major recommendations about antiplatelet therapy made by some of the most prestigious learned societies will be presented.
Collapse
Affiliation(s)
- J M Paradis
- University of Montreal, Montreal, Montreal Heart Institute, Faculty of Medicine, Montreal, Québec, Canada
| | | | | |
Collapse
|
41
|
Majdoub MA, Sauguet A, Tchetche D, Ducrocq G, Benamer H, Himbert D, Aubry P, Feldman LJ, Steg PG, Juliard JM. [Treatment of intrastent restenosis by drug eluting stents: experience from one cardiology centre]. Arch Mal Coeur Vaiss 2007; 100:184-8. [PMID: 17536421] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/15/2023]
Abstract
Many interventional treatments have been proposed for intrastent stenosis, in particular by drug-eluting stents, with encouraging results. The aim of this study was to assess the clinical outcome of patients with restenosis of an ordinary uncovered stent treated by a drug eluting stent in a prospective series. The register included 43 patients (50 intrastent restenoses) treated by a drug eluting stent (Cypher or Taxus). The restenosis lesion was focal in 32% of cases with an average length of 14.8 +/- 8 mm and diameter inferior to 2.5 mm in 48% of cases. A Cypher stent was implanted in 44% of cases and a Taxus stent in 56% of cases. After an average follow-up of 6.7 +/- 1.3 months, the major adverse cardiac event rate was 9.3%. It included one transmural infarct in a patient, due to stent thrombosis, and symptomatic restenoses in 3 patients (clinical restenosis rate: 7%). An angiographic control was performed in 15 patients (35%) identifying focal restenosis at the exit of the stent in the 3 symptomatic patients. As in previously reported studies, these results show that with well conducted platelet antiaggregant therapy, the treatment of intrastent restenosis with a drug eluting stent is effective with a low rate of adverse cardiovascular events which compares favourably with previously proposed techniques of management.
Collapse
Affiliation(s)
- M A Majdoub
- Département de cardiologie, Pr Alec Vahanian, hôpital Bichat, 46 rue Henri Huchard, 75877 Paris
| | | | | | | | | | | | | | | | | | | |
Collapse
|